| [1] |
Yin L，Duan JJ，Bian XW，et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1): 61.
|
| [2] |
So JY，Ohm J，Lipkowitz S，et al. Triple negative breast cancer（TNBC）: Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options[J]. Pharmacol Ther, 2022, 237: 108253.
|
| [3] |
Zagami P，Carey LA. Triple negative breast cancer: Pitfalls and progress[J]. npj Breast Cancer, 2022, 8(1): 95.
|
| [4] |
Johansson ALV，Trewin CB，Hjerkind KV，et al. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort[J]. Int J Cancer, 2019, 144(6): 1251–1261.
|
| [5] |
Bardia A，Hurvitz SA，Tolaney SM，et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. New England Journal of Medicine, 2021, 384(16): 1529–1541.
|
| [6] |
Cortes J，Rugo HS，Cescon DW，et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. New England Journal of Medicine, 2022, 387(3): 217–26.
|
| [7] |
贾闵羽.雄激素受体与三阴性乳腺癌相关研究现状[J].中国医学科学院学报, 2023, 45(02): 303–310.
|
| [8] |
O'brien J，Hayder H，Zayed Y，et al. Overview of MicroRNA Biogenesis，Mechanisms of Actions，and Circulation[J]. Front Endocrinol（Lausanne）, 2018, 9: 402.
|
| [9] |
Piasecka D，Braun M，Kordek R，et al. MicroRNAs in regulation of triple-negative breast cancer progression[J]. J Cancer Res Clin Oncol, 2018, 144(8): 1401–1411.
|
| [10] |
Chen Q，Liu Y，Gao Y，et al. A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers[J]. Scientific Data, 2022, 9(1): 587.
|
| [11] |
Sabit H，Cevik E，Tombuloglu H，et al. Triple negative breast cancer in the era of miRNA[J]. Crit Rev Oncol Hematol, 2021, 157: 103196.
|
| [12] |
Xu J，Wu KJ，Jia QJ，et al. Roles of miRNA and lncRNA in triple-negative breast cancer[J]. J Zhejiang Univ Sci B, 2020, 21(9): 673–89.
|
| [13] |
Panella R，Cotton CA，Maymi VA，et al. Targeting of microRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer[J]. Biomedicines, 2023, 11(5): 1470.
|
| [14] |
Kahraman M，Röske A，Laufer T，et al. MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer[J]. Sci Rep, 2018, 8(1): 11584.
|
| [15] |
Abdel-Sater F，Najar M，Fayyad-Kazan H. Triple negative breast cancer: microRNA expression profile and novel discriminators according to BRCA1 status[J]. J Cell Physiol, 2020, 235(6): 5204–5212.
|
| [16] |
Pollard J，Burns PA，Hughes TA，et al. Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities[J]. Pathobiology, 2018, 85(4): 220–6.
|
| [17] |
Sharifi Z，Talkhabi M，Taleahmad S. Identification of potential microRNA diagnostic panels and uncovering regulatory mechanisms in breast cancer pathogenesis[J]. Scientific Reports, 2022, 12(1): 20135.
|
| [18] |
Turkistani S，Sugita BM，Fadda P，et al. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer[J]. BMC Cancer, 2021, 21(1): 861.
|
| [19] |
Hironaka-Mitsuhashi A，Matsuzaki J，Takahashi RU，et al. A tissue microRNA signature that predicts the prognosis of breast cancer in young women[J]. PLoS One, 2017, 12(11): e0187638.
|
| [20] |
Qattan A. Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease[J]. Int J Mol Sci, 2020, 21(23): 8905.
|
| [21] |
Grimaldi AM，Salvatore M，Incoronato M. miRNA-Based Therapeutics in Breast Cancer: A Systematic Review[J]. Front Oncol, 2021, 11: 668464.
|
| [22] |
Cheng Y，Dong L，Zhang J，et al. Recent advances in microRNA detection[J]. Analyst, 2018, 143(8): 1758–1774.
|
| [23] |
Dave VP，Ngo TA，Pernestig AK，et al. MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics[J]. Lab Invest, 2019, 99(4): 452–469.
|
| [24] |
Loudig O，Liu C，Rohan T，et al. Retrospective MicroRNA Sequencing: Complementary DNA Library Preparation Protocol Using Formalin-fixed Paraffin-embedded RNA Specimens. J Vis Exp, 2018, 5:(135): 57471.
|